Oncology News | pharmaphorum

News

Merck bulks up in haematology, buying Imago for $1.35bn

While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago B

News

GSK's pullback from cell therapy continues as Immatics allia...

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.

News

Takeda's Iclusig bests imatinib in first-line leukaemia tria...

Takeda has a chance of breaking into new territory with its blood cancer therapy Iclusig, after the drug performed better than mainstay therapy imatinib in a phase 3 study of adults with ne

News

Astellas nabs lead in claudin 18.2 after positive stomach ca...

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or gastroesopha

News

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

ImmunoGen, Inc.

News

Lantheus on POINT in radio-oncology with $2bn licensing deal

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.

Merck bulks up in haematology, buying Imago for $1.35bn

GSK's pullback from cell therapy continues as Immatics allia...

Takeda's Iclusig bests imatinib in first-line leukaemia tria...

Astellas nabs lead in claudin 18.2 after positive stomach ca...

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

Lantheus on POINT in radio-oncology with $2bn licensing deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks